[en] Crohn's disease and ulcerative colitis known as inflammatory bowel diseases (IBD) are chronic immuno-inflammatory pathologies of the gastrointestinal tract. These diseases are multifactorial, polygenic and of unknown etiology. Clinical presentation is non-specific and diagnosis is based on clinical, endoscopic, radiological and histological criteria. Novel markers are needed to improve early diagnosis and classification of these pathologies. We performed a study with 120 serum samples collected from patients classified in 4 groups (30 Crohn, 30 ulcerative colitis, 30 inflammatory controls and 30 healthy controls) according to accredited criteria. We compared protein sera profiles obtained with a Surface Enhanced Laser Desorption Ionization-Time of Flight-Mass Spectrometer (SELDI-TOF-MS). Data analysis with univariate process and a multivariate statistical method based on multiple decision trees algorithms allowed us to select some potential biomarkers. Four of them were identified by mass spectrometry and antibody based methods. Multivariate analysis generated models that could classify samples with good sensitivity and specificity (minimum 80%) discriminating groups of patients. This analysis was used as a tool to classify peaks according to differences in level on spectra through the four categories of patients. Four biomarkers showing important diagnostic value were purified, identified (PF4, MRP8, FIBA and Hpalpha2) and two of these: PF4 and Hpalpha2 were detected in sera by classical methods. SELDI-TOF-MS technology and use of the multiple decision trees method led to protein biomarker patterns analysis and allowed the selection of potential individual biomarkers. Their downstream identification may reveal to be helpful for IBD classification and etiology understanding.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Korzenik J.R. Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol 39 (2005) S59-S65
Schreiber S., Rosenstiel P., Albrecht M., Hampe J., and Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6 (2005) 376-388
Danese S., Sans M., and Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 3 (2004) 394-400
Podolsky D.K. Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterol Belg 60 (1997) 163-165
Neuman M.G. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol 13 (2004) 309-316
Solem C.A., Loftus Jr. E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35 (1994) 231-235
Tibble J.A., Sigthorsson G., Foster R., Forgacs I., and Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123 (2002) 450-460
Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., and Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000) 15-22
Tibble J.A., and Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 7 (2001) 460-465
Vermeire S., Van Assche G., and Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 661-665
Bunn S.K., Bisset W.M., Main M.J., and Golden B.E. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 32 (2001) 171-177
Vermeire S., Joossens S., Peeters M., Monsuur F., Marien G., Bossuyt X., et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 120 (2001) 827-833
Joossens S., Daperno M., Shums Z., Van Steen K., Goeken J.A., Trapani C., et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 50 (2004) 1422-1425
Joossens S., Reinisch W., Vermeire S., Sendid B., Poulain D., Peeters M., et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122 (2002) 1242-1247
Klebl F.H., Bataille F., Bertea C.R., Herfarth H., Hofstadter F., Scholmerich J., et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 9 (2003) 302-307
Cho J.H. Advances in the genetics of inflammatory bowel disease. Curr Gastroenterol Rep 6 (2004) 467-473
Ahmad T., Tamboli C.P., Jewell D., and Colombel J.F. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126 (2004) 1533-1549
Sands B.E. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126 (2004) 1518-1532
Vermeire S., Peeters M., and Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 47 (2000) 44-48
Egan L.J., and Sandborn W.J. Advances in the treatment of Crohn's disease. Gastroenterology 126 (2004) 1574-1581
Hanauer S.B., and Thisted R.A. Treatment of Crohn's disease: the "long" of it. Gastroenterology 128 (2005) 2164-2166
Hanauer S.B., and Present D.H. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3 (2003) 81-92
Hanauer S.B. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17 (2003) 131-137
Felley-Bosco E., and Andre M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract 200 (2004) 129-133
Aderem A., and Smith K.D. A systems approach to dissecting immunity and inflammation. Semin Immunol 16 (2004) 55-67
Xiao Z., Prieto D., Conrads T.P., Veenstra T.D., and Issaq H.J. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 230 (2005) 95-106
Seibert V., Ebert M.P., and Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 4 (2005) 16-26
Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
Rodland K.D. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 37 (2004) 579-583
Petricoin E.F., and Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15 (2004) 24-30
Merchant M., and Weinberger S.R. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21 (2000) 1164-1177
Alaiya A., Al-Mohanna M., and Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 4 (2005) 1213-1222
de Seny D., Fillet M., Meuwis M.A., Geurts P., Lutteri L., Ribbens C., et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 52 (2005) 3801-3812
Conrads T.P., Fusaro V.A., Ross S., Johann D., Rajapakse V., Hitt B.A., et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 11 (2004) 163-178
Gasche C., Scholmerich J., Brynskov J., D'Haens G., Hanauer S.B., Irvine E.J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology Vienna 1998. Inflamm Bowel Dis 6 (2000) 8-15
Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., and Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
Sachar D.B. Behaviour of Crohn's disease according to the Vienna classification. Gut 51 (2002) 614 [author reply-5]
Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
American Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 136 (1987) 225-244
Geurts P., Fillet M., de Seny D., Meuwis M.A., Malaise M., Merville M.P., et al. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21 (2005) 3138-3145
In: Wehenkel L. (Ed). Automatic learning techniques in power systems (1998), Kluwer Academic
Fillet M., Cren-Olive C., Renert A.F., Piette J., Vandermoere F., Rolando C., et al. Differential expression of proteins in response to ceramide-mediated stress signal in colon cancer cells by 2-D gel electrophoresis and MALDI-TOF-MS. J Proteome Res 4 (2005) 870-880
Semmes O.J., Feng Z., Adam B.L., Banez L.L., Bigbee W.L., Campos D., et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I Assessment of platform reproducibility. Clin Chem 51 (2005) 102-112
Petricoin E.F., Fishman D.A., Conrads T.P., Veenstra T.D., and Liotta L.A. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 4 (2004) 2357-2360
Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 30 (2004) 379-385
Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 37 (2005) 1162-1167
Stoeckle M.Y., and Barker K.A. Two burgeoning families of platelet factor 4-related proteins: mediators of the inflammatory response. New Biol 2 (1990) 313-323
Danese S., Motte Cd Cde L., and Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 99 (2004) 938-945
Knot E., Ten Cate J.W., Leeksma O.C., Tytgat G.N., and Vreeken J. No evidence for a prethrombotic state in stable chronic inflammatory bowel disease. J Clin Pathol 36 (1983) 1387-1390
Vrij A.A., Rijken J., Van Wersch J.W., and Stockbrugger R.W. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest 30 (2000) 188-194
Gupta S.K., Hassel T., and Singh J.P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92 (1995) 7799-7803
Van Damme J., Struyf S., and Opdenakker G. Chemokine-protease interactions in cancer. Semin Cancer Biol 14 (2004) 201-208
Green C.J., Charles R.S., Edwards B.F., and Johnson P.H. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol 9 (1989) 1445-1451
Mosesson M.W. Fibrinogen and fibrin structure and functions. J Thromb Haemost 3 (2005) 1894-1904
Chamouard P., Grunebaum L., Duclos B., Wiesel L., and Cazenave J.P. Biological manifestations of a prethrombotic state in developmental Crohn's disease. Gastroenterol Clin Biol 14 (1990) 203-208
Wisen O., and Gardlund B. Hemostasis in Crohn's disease: low factor XIII levels in active disease. Scand J Gastroenterol 23 (1988) 961-966
Frosch M., Vogl T., Seeliger S., Wulffraat N., Kuis W., Viemann D., et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48 (2003) 2622-2626
Frosch M., Strey A., Vogl T., Wulffraat N.M., Kuis W., Sunderkotter C., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43 (2000) 628-637
Kane D., Roth J., Frosch M., Vogl T., Bresnihan B., and FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 48 (2003) 1676-1685
Vermeire S., Van Assche G., and Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 55 (2006) 426-431
Vucelic B., Milicic D., Krznaric Z., Korac B., Sentic M., Hadzic N., et al. Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease. Acta Med Austriaca 18 (1991) 100-105
Kupcova V., Turecky L., Detkova Z., Prikazska M., and Keleova A. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52 (2003) 89-93
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
